434 related articles for article (PubMed ID: 1903080)
1. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
Longridge DJ; Follenfant MJ; Ford AJ
Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
[TBL] [Abstract][Full Text] [Related]
2. Enhanced myocardial salvage by maintenance of microvascular patency following initial thrombolysis with recombinant tissue plasminogen activator.
Longridge DJ; Follenfant MJ; Maxwell MP; Ford AJ; Hughes B
Cardiovasc Res; 1990 Sep; 24(9):697-706. PubMed ID: 2121357
[TBL] [Abstract][Full Text] [Related]
3. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
Martin U; Fischer S; Sponer G
J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
[TBL] [Abstract][Full Text] [Related]
4. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
[TBL] [Abstract][Full Text] [Related]
5. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
6. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
Rebello SS; Huang J; Saito K; Saucedo JF; Bates ER; Lucchesi BR
Eur J Pharmacol; 1999 Jun; 374(3):399-410. PubMed ID: 10422784
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
[TBL] [Abstract][Full Text] [Related]
10. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
[TBL] [Abstract][Full Text] [Related]
11. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
12. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
[TBL] [Abstract][Full Text] [Related]
13. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
Martin U; Sponer G; König R; Smolarz A; Meyer-Sabellek W; Strein K
Blood Coagul Fibrinolysis; 1992 Apr; 3(2):139-47. PubMed ID: 1606285
[TBL] [Abstract][Full Text] [Related]
14. Enhanced thrombolysis, reduced coronary reocclusion and limitation of infarct size with liposomal prostaglandin E1 in a canine thrombolysis model.
Feld S; Li G; Amirian J; Felli P; Vaughn WK; Accad M; Tolleson TR; Swenson C; Ostro M; Smalling RW
J Am Coll Cardiol; 1994 Nov; 24(5):1382-90. PubMed ID: 7930264
[TBL] [Abstract][Full Text] [Related]
15. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
[TBL] [Abstract][Full Text] [Related]
17. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
19. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
Schneider J
Thromb Res; 1991 Dec; 64(6):677-89. PubMed ID: 1798957
[TBL] [Abstract][Full Text] [Related]
20. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
